FOLH1 and prostate carcinoma: After the implementation and widespread use of [18F]PSMA-1007 in prostate cancer management, clinicians have been reporting a high number of benign, non-prostatic structures, in particular ganglia, in comparison to the current most widely used PSMA PET tracer [68Ga]Ga-PSMA-11.